{"nctId":"NCT00184717","briefTitle":"Growth Hormone Treatment in Children Born Small for Gestational Age (SGA)","startDateStruct":{"date":"2004-08-18","type":"ACTUAL"},"conditions":["Foetal Growth Problem","Small for Gestational Age"],"count":98,"armGroups":[{"label":"0.033 mg / NN-220","type":"EXPERIMENTAL","interventionNames":["Drug: somatropin"]},{"label":"0.067 mg / NN-220","type":"EXPERIMENTAL","interventionNames":["Drug: somatropin"]},{"label":"No treatment","type":"NO_INTERVENTION","interventionNames":[]},{"label":"No treatment --> 0.033 mg","type":"EXPERIMENTAL","interventionNames":["Drug: somatropin"]},{"label":"No treatment --> 0.067 mg","type":"EXPERIMENTAL","interventionNames":["Drug: somatropin"]}],"interventions":[{"name":"somatropin","otherNames":[]},{"name":"somatropin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* For MAIN period (GHLIQUID-1516):\n* Born small for gestational age (SGA) with birth weight and birth length below the 10th percentile for gestational age, and additional either birth length below or equal to -2.0 standard deviation score (SDS) or birth weight below or equal to -2.0 SDS for gestational age\n* Growth failure with height at -2.0 SDS or below for chronological age (CA)\n* Normal growth hormone (GH) production, defined as peak GH level \\> 10 ng/mL in one GH provocation test\n* For EXTENSION period (GHLIQUID-1517):\n* Subjects who completed the main period\n* Chronological age (CA) for boys at least 4 years, but maximum 11 years\n* Chronological age (CA) for girls at least 4 years, but maximum 10 years\n\nExclusion Criteria:\n\n* Subjects with diabetes mellitus\n* Subjects suffering from malignancy\n* Several medical conditions","healthyVolunteers":false,"sex":"ALL","minimumAge":"3 Years","maximumAge":"8 Years","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Height Standard Deviation Score (SDS) for Chronological Age (CA) at Week 260 - Subjects Received NN220 Treatment for 5 Years","description":"Height SDS for chronological age were derived as follow; {Height - mean (age, sex)}/ SD (age, sex), where mean (age, sex) and SD (age, sex) were mean and SD of height for corresponding chronological age and sex (data of those in 2000). Height SDS was calculated using mean of three height observations at corresponding visit","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.9488","spread":"0.6368"},{"groupId":"OG001","value":"-2.9047","spread":"0.6718"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2066","spread":"0.1102"},{"groupId":"OG001","value":"2.0247","spread":"0.1083"}]}]}]},{"type":"PRIMARY","title":"Change in Height Standard Deviation Score (SDS) for Chronological Age (CA) at Week 208 - Subjects Received NN220 Treatment for 4 Years","description":"Height SDS for chronological age were derived as follow; {Height - mean (age, sex)}/ SD (age, sex), where mean (age, sex) and SD (age, sex) were mean and SD of height for corresponding chronological age and sex (data of those in 2000). Height SDS was calculated using mean of three height observations at corresponding visit","classes":[{"categories":[{"measurements":[{"groupId":"OG002","value":"-2.9603","spread":"0.6689"},{"groupId":"OG003","value":"-2.7481","spread":"0.3524"}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"1.0997","spread":"0.2453"},{"groupId":"OG003","value":"1.9151","spread":"0.2275"}]}]}]},{"type":"SECONDARY","title":"Yearly Height Velocity SDS for Chronological Age - Subjects Received NN220 Treatment for 5 Years","description":"Yearly Height velocity SDS for chronological age were summarised and graphically presented","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6299","spread":"0.9738"},{"groupId":"OG001","value":"-2.0303","spread":"1.4527"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4717","spread":"1.9848"},{"groupId":"OG001","value":"4.7875","spread":"1.9365"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1344","spread":"1.2782"},{"groupId":"OG001","value":"2.8877","spread":"1.1272"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8015","spread":"1.0583"},{"groupId":"OG001","value":"2.1641","spread":"1.5929"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3991","spread":"1.3006"},{"groupId":"OG001","value":"1.4724","spread":"1.8696"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4612","spread":"2.1558"},{"groupId":"OG001","value":"0.7973","spread":"2.1822"}]}]}]},{"type":"SECONDARY","title":"Yearly Height Velocity SDS for Chronological Age - Subjects Received NN220 Treatment for 4 Years","description":"Yearly Height velocity SDS for chronological age were summarised and graphically presented","classes":[{"categories":[{"measurements":[{"groupId":"OG002","value":"0.073","spread":"1.5681"},{"groupId":"OG003","value":"-1.356","spread":"0.708"}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"2.1677","spread":"0.61"},{"groupId":"OG003","value":"5.9303","spread":"1.2096"}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"1.5268","spread":"1.1715"},{"groupId":"OG003","value":"3.3979","spread":"1.0542"}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"1.7617","spread":"2.0956"},{"groupId":"OG003","value":"2.3539","spread":"1.3149"}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"0.5475","spread":"1.6055"},{"groupId":"OG003","value":"2.199","spread":"1.5973"}]}]}]},{"type":"SECONDARY","title":"Change in Bone Age (Left Hand X-Ray) at Week 260 - Subjects Received NN220 Treatment for 5 Years","description":"Bone age is measured as years and months (displayed as xx.x years). Change in Bone age = Bone age at 52\\*i weeks - Bone age at 52\\*(i-1) weeks, i=1, 2, ….","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.79","spread":"1.05"},{"groupId":"OG001","value":"7.15","spread":"1.05"}]}]}]},{"type":"SECONDARY","title":"Change in Bone Age (Left Hand X-Ray) at Week 208 - Subjects Received NN220 Treatment for 4 Years","description":"Bone age is measured as years and months (displayed as xx.x years).Change in Bone age = Bone age at 52\\*i weeks - Bone age at 52\\*(i-1) weeks, i=1, 2, ….","classes":[{"categories":[{"measurements":[{"groupId":"OG002","value":"6.54","spread":"1.26"},{"groupId":"OG003","value":"5.6","spread":"1.68"}]}]}]},{"type":"SECONDARY","title":"Adverse Events - Subjects Received NN220 Treatment for 5 Years","description":"Occurrence of Adverse Events (AEs) during treatment period (TEAEs), occurrence of possibly/probably related AEs during the treatment period, and occurrence of Serious Adverse Events (SAEs) during the treatment period. An AE is any undesirable medical event occurring to a subject in a clinical trial, whether or not related to the trial product(s). An SAE is an experience that at any dose is fatal, life-threatening, disabling or which results in the patient being hospitalised or, if already in hospital, that hospitalisation is prolonged, or ocurrence of congenital anomaly","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Adverse Events - Subjects Received NN220 Treatment for 4 Years","description":"Occurrence of Adverse Events (AEs) during treatment period (TEAEs), occurrence of possibly/probably related AEs during the treatment period, and occurrence of Serious Adverse Events (SAEs) during the treatment period. An AE is any undesirable medical event occurring to a subject in a clinical trial, whether or not related to the trial product(s). An SAE is an experience that at any dose is fatal, life-threatening, disabling or which results in the patient being hospitalised or, if already in hospital, that hospitalisation is prolonged, or ocurrence of congenital anomaly","classes":[{"categories":[{"measurements":[{"groupId":"OG002","value":"7","spread":null},{"groupId":"OG003","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":12,"n":31},"commonTop":["Nasopharyngitis","Upper respiratory tract inflammation","Influenza","Bronchitis","Pharyngitis"]}}}